Literature DB >> 2905367

Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

G Delitala1, P Tomasi, R Virdis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2905367     DOI： 10.1007/BF03349081

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  169 in total

1.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

Authors:  S S Yen; T M Siler; G W DeVane
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

2.  Adrenergic blockade and the corticosteroid and growth hormone responses to methylamphetamine.

Authors:  L Rees; P W Butler; C Gosling; G M Besser
Journal:  Nature       Date:  1970-11-07       Impact factor: 49.962

3.  The effect of adrenergic receptor blockade on the exercise-induced serum growth hormone rise in normals and juvenile diabetics.

Authors:  A P Hansen
Journal:  J Clin Endocrinol Metab       Date:  1971-11       Impact factor: 5.958

4.  Stimulation of human-growth-hormone secretion by L-dopa.

Authors:  A E Boyd; H E Lebovitz; J B Pfeiffer
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

5.  Effect of 1-5 hydroxytryptophan infusion on growth hormone and prolactin secretion in man.

Authors:  I Lancranjan; A Wirz-Justice; W Pühringer; E Del Pozo
Journal:  J Clin Endocrinol Metab       Date:  1977-09       Impact factor: 5.958

6.  Suppression by thyrotropin-releasing hormone (TRH) of human growth hormone release induced by L-dopa.

Authors:  K Maeda; Y Kato; K Chihara; S Ogo; Y Iwasaki
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

7.  Binding sites for growth hormone releasing factor on rat anterior pituitary cells.

Authors:  H Seifert; M Perrin; J Rivier; W Vale
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

8.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Growth hormone releasing factor (hpGRF)-stimulation test in normal controls and acromegalic patients.

Authors:  K von Werder; O A Müller; R Hartl; M Losa; G K Stalla
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

10.  Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.

Authors:  A L Barkan; R P Kelch; N J Hopwood; I Z Beitins
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958
View more
  4 in total

1.  Blindness influences the growth of institutionalized prepubertal subjects.

Authors:  A Bellastella; A A Sinisi; C Raiola; L Perrone; S Iorio; F Parlato; A Mazzuca; M Faggiano
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Interaction of glucose and pyridostigmine on the secretion of growth hormone (GH) induced by GH-releasing hormone (GHRH).

Authors:  G Delitala; P A Tomasi; M Palermo; P Fresu
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

3.  Interaction of L-dopa and GHRH on GH secretion in normal men.

Authors:  J Alba-Roth; C von Creytz; G Mehltretter; J Schopohl; O A Müller; K von Werder
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

4.  Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

Authors:  C A Jaffe; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.